Abstract:Background/Objectives: Primary biliary cholangitis (PBC) is an autoimmune chronic cholestatic disease of the liver that symptomatically can present with pruritus and fatigue. Its established first- and second-line therapies are ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) although they provide limited symptom management. Liver transplantation offers a potentially curative therapeutic option in refractory cases progressing to cirrhosis. Novel research published after the current guidelines highlights the importance of providing an up-to-date analysis of treatment options available. Methods: In this study, we conducted a literature search using Pubmed, Ovid Medline, and SCOPUS to provide a narrative review of first-line, second-line, and emerging therapies in PBC. Results: UDCA has been well established as a long-term, safe therapy within the literature although it is possible that treatment dosage can be further optimised in refractory patients. It has a favourable side effect profile. Despite improving biochemical markers, histopathological profile, and overall outcomes, up to 30–40% of patients are refractory to it. Age and sex are highlighted as independent indicators of non-responsiveness. This necessitates effective second-line therapies. Future trials could aim to investigate UDCA as a co-first-line therapy. Further supporting results for OCA were found in the interim extension trial of the seminal POISE study. The long-term phase 4 COBOLT trial is still awaiting results to further assess the complications, adherence, and potential adverse effects. It is a viable option in UDCA-refractory patients. The high incidence rate of dose-related pruritis indicates that alternative second-line options are needed. Bezafibrate is an off-label antilipemic agent that shows promise as a prospective second-line therapy option. The landmark BEZURSO trial alleviated some efficacy and safety concerns, but it remains associated with elevated serum creatinine; thus, it should be considered with caution. Other prospective second-line therapies are budesonide, triple therapy, and novel agents such as seladelpar and elafibranor. Conclusions: UDCA should remain the treatment of choice for PBC, though perhaps not as monotherapy. With further investigation, BF shows promise as a new second-line therapy alongside OCA, which it may outperform.

Therapeutic Role of Bile Acids and Nuclear Receptor Agonists in Fibrosing Cholangiopathies

Obeticholic Acid—A Pharmacological and Clinical Review

Novel and emerging therapies for cholestatic liver diseases

Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments

PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases

Novel therapeutic targets in primary biliary cirrhosis

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis

New Therapies for Primary Biliary Cirrhosis

Primary biliary cholangitis: pathogenesis and therapeutic opportunities

Bile acid-mediated signaling in cholestatic liver diseases

Current Therapeutics in Primary Sclerosing Cholangitis

Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics

Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid

Advances in the Treatment of Primary Biliary Cholangitis

Obeticholic acid for the treatment of primary biliary cirrhosis

Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases

New Treatment Paradigms in Primary Biliary Cholangitis

Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis

Revisiting PPAR agonists: novel perspectives in the treatment of primary biliary cholangitis

Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis